Overview
|
Vermillion is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Our efforts are focused on oncology, hematology, cardiology and women’s health. Ovarian CancerVermillion is evaluating and validating biomarkers that may expand our ability to enter into other diagnostic arenas in the field of ovarian cancer. Peripheral Arterial Disease (PAD)We are developing VASCLIR® in collaboration with Stanford University to aid physicians in the diagnosis of PAD, which is a disorder affecting approximately 12 million Americans and that is under-diagnosed and under-treated. |
Alliances
Vermillion collaborates with scientists at leading academic institutions such as Johns Hopkins University, M.D. Anderson and Stanford. Our scientific know-how discovers novel biomarkers for a variety of unmet clinical needs.
 |
